4Johnson JR,Temple R. Food and drug administration requirements for approval of new anti-cancer drugs[J]. Cancer Treat Rep, 1985,69(10) : 1155-1157.
5Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30:a quality of life instrument for use in international clinical trials in oncology [J]. J Natl Cancer Inst, 1993,85 (5) : 365-376.
6Aaronson NK, Cull A, Kaasa S, et al. The EORTC modular approach to quality of life assessment in ontology [J]. Int J Ment Health, 1994,23 (4):75-96.
7Blazeby JM, Alderson D, Winstone K, et al. Development of an EORTC Questionnaire Module to be used in quality of life assessment for patients with oesophageal cancer [J]. Eur J Cancer, 1996, 32(11):1912-1917.
8Blazeby JM,Conroy T, Hammerlid E,et al.Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18,to assess quality of life in patients with oesophageal cancer[J]. Eur J Cancer, 2003, 39 (10):1384-1394.
9Fayers PM, Asronson NK, Bjordal K, et al. On behalf of the EORTC Quality of Life Study Group. The EORTC QLQ-C30 scoring manual[M].3^rd ed.Brussels'EORTC, 2001.
10Ross P,Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil(PVI 5-Fu) with epirubicin, cisplatin, and PVI 5-Fu in advanced esophagogas- tric cancer[J]. J Clin Oncol, 2002, 20(8):1996-2004.
